Alzheimer’s
FDA fast-tracked approval of Alzheimer’s drug lecanemab despite serious risk, with NO huge upside
The mainstream is always talking about the benefits outweighing the risks when it comes to Big Pharma’s drugs. But the newly-approved Alzheimer’s drug lecanemab carries a whopper of a life-threatening risk of brain swelling and bleeding… while only slowing disease progression for about five months.